作者
Bianca J. Lee,Jacob A. Boyer,G. Leslie Burnett,Arun P. Thottumkara,Nidhi Tibrewal,Stacy Wilson,Tientien Hsieh,Abby Marquez,Edward Lorenzana,James Evans,Laura Hulea,Gert Kiss,Hui Liu,Dong Hun Lee,Ola Larsson,Shannon McLaughlan,Ivan Topisirović,Zhengping Wang,Zhican Wang,Yiyang Zhao,David Wildes,James B. Aggen,Mallika Singh,Adrian L. Gill,Jacqueline A.M. Smith,Neal Rosen
摘要
The clinical benefits of pan-mTOR active-site inhibitors are limited by toxicity and relief of feedback inhibition of receptor expression. To address these limitations, we designed a series of compounds that selectively inhibit mTORC1 and not mTORC2. These 'bi-steric inhibitors' comprise a rapamycin-like core moiety covalently linked to an mTOR active-site inhibitor. Structural modification of these components modulated their affinities for their binding sites on mTOR and the selectivity of the bi-steric compound. mTORC1-selective compounds potently inhibited 4EBP1 phosphorylation and caused regressions of breast cancer xenografts. Inhibition of 4EBP1 phosphorylation was sufficient to block cancer cell growth and was necessary for maximal antitumor activity. At mTORC1-selective doses, these compounds do not alter glucose tolerance, nor do they relieve AKT-dependent feedback inhibition of HER3. Thus, in preclinical models, selective inhibitors of mTORC1 potently inhibit tumor growth while causing less toxicity and receptor reactivation as compared to pan-mTOR inhibitors. Design of a bivalent inhibitor containing an ATP-competitive moiety and rapamycin-modified FRB binding ligand that selectively inhibits mTORC1 results in potent and durable inhibition of 4EBP1 phosphorylation and cell proliferation in vitro and in vivo.